Zika Virus: Updates to Clinical Guidance and Recommendations for Pregnant Women and Infants

> Clinician Outreach and Communication Activity (COCA) Webinar July 27, 2017



Accreditation Statements

CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians. The Centers for Disease Control and Prevention designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the <u>American Nurses Credentialing</u> Center's Commission on Accreditation. This activity provides 1.0 contact hour.

IACET CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 1.0 CEU's for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designed for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number 98614.

CPE: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is a designated event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is 0387-0000-17-156-L04-P and enduring 0387-0000-17-156-H04-P course category. Course Category: This activity has been designated as knowledge-based. Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor

AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education in the jurisdictions which recognize AAVSB RACE approval. Please contact the AAVSB RACE Program at race@aavsb.org if you have any comments/concerns regarding this program's validity or relevancy to the veterinary profession.

CPH: The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credit for this program.

Continuing Education Disclaimer

CDC, our planners, presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.

Planners have reviewed content to ensure there is no bias.

TODAY'S FIRST PRESENTER



Titilope Oduyebo, MD, MPH

Medical Officer Division of Reproductive Health National Center for Chronic Disease Prevention and Health Promotion Centers for Disease Control and Prevention


TODAY'S SECOND PRESENTER



Dana Meaney-Delman, MD, MPH

Senior Medical Officer, Office of Infectious Diseases National Center for Emerging & Zoonotic Infectious Diseases Centers for Disease Control and Prevention

TODAY'S THIRD PRESENTER



Sasapin Grace Prakalapakorn, MD, MPH

Assistant Professor of Ophthalmology and Pediatrics Duke Ophthalmology Duke University School of Medicine

To Ask a Question

Using the Webinar System

- Click the Q&A button in the webinar
- Type your question in the Q&A box
- Submit your question

CDC'S Response to Zika

Update: Interim Guidance for Healthcare Providers Caring for Pregnant Women with Possible Zika Virus Exposure—United States, July 2017

Titilope Oduyebo, MD, MPH Lead, Clinical Team, Pregnancy & Birth Defects Task Force CDC's Zika Virus Response





U.S. Department of Health and Human Services Centers for Disease Control and Prevention

July 27, 2017

Topics to be covered

- Updated interim guidance for pregnant women
 - Emerging data and current state of epidemic
 - Updated recommendations for testing and interpretation of results
- Pregnancy outcomes after maternal Zika virus exposure
 - Zika Pregnancy and Infant Registries
 - Findings from the Zika Pregnancy and Infant Registries and implications
- Pediatric ophthalmologic findings among infants following congenital Zika virus infection
 - Ocular findings among infants with congenital Zika virus infection
 - CDC guidance for ophthalmologic screening for infants with possible congenital infection


Emerging Data and Current State of Epidemic

Big Picture: Emerging Data and Implications for Zika Testing

- Declining trend in reported cases of Zika infection leads to lower pretest probability and a higher proportion of positive test results being false
- Zika virus IgM antibodies can persist for months in some people, which could make it difficult for healthcare providers to use Zika IgM test results to determine whether an infection occurred during the current pregnancy versus prior to conception

Declining Trends in Reported Zika Cases in the Americas


Confirmed and suspected Zika virus in the Americas, 2015–2017 (as of May 25, 2017)



PAHO Regional Zika Epidemiological Update (May 25, 2017): _http://www.paho.org/hq/index.php?option=com_content&view=article&id=11599&Itemid=41691&Iang=en__

Declining Trends in Reported Zika Virus Disease Cases in the US


Laboratory-confirmed Zika virus disease cases in US states and Washington, DC, 2016–2017 (as of July 5, 2017)



Hypothetical Example of Disease Prevalence and Implications for Test Performance : Disease is Common

Example 1: Disease is common


- 40 out of 100 patients in this area have the disease
- Test specificity: 98% (high)
- Test sensitivity: 98% (high)



Hypothetical Example of Disease Prevalence and Implications for Test Performance : Disease is Rare

Example 2: Disease is rare

- 1 out of 100 patients in this area have the disease
- Test specificity: 98% (high)
- Test sensitivity: 98% (high)



Prolonged Zika Virus IgM


- Zika virus IgM can persist beyond 12 weeks in a subset of infected people
- Unpublished preliminary data from Zika Virus Persistence (ZiPer) Study of persons with NAT-confirmed Zika virus disease
 - Zika virus IgM detected in 100% of participants at 8-15 days after symptom onset
 - Detectable IgM levels decreased over time, however some participants remained IgM positive for more than 7 months after symptom onset



CDC HAN-00402: https://emergency.cdc.gov/han/han00402.asp

Pregnant woman with possible exposure to Zika virus before current pregnancy

A positive Zika IgM antibody test result could mean....



Zika virus infection during current pregnancy, meaning pregnancy is likely at risk from Zika

Zika virus infection before current pregnancy, meaning pregnancy is likely not at risk from Zika

False positive result, meaning pregnancy is likely not at risk from Zika


Updated Guidance

Updated Guidance: Emphasis on Shared Decision-Making Model

- Updated guidance emphasizes a shared decision-making model for testing and screening pregnant women
- Clinical judgment is imperative
 - Decisions about testing should be informed by factors such as
 - Length of possible exposure
 - Type or location of travel
 - Intensity of Zika transmission
 - Presence of symptoms
 - Prevention measures
 - Preferences or concerns
 - Jurisdictional recommendations




Symptomatic Pregnant Women with Possible Zika virus Exposure



Updated Guidance: Ask Pregnant Women


ASK PREGNANT WOMEN about

- Before and during current pregnancy:
 - Travel or residence in areas with risk for Zika virus transmission
 - Possible sexual exposure
- Diagnosis of laboratory-confirmed Zika virus infection before the current pregnancy
- Symptoms of Zika virus infection during the current pregnancy




If no symptoms reported, refer to asymptomatic algorithm.

Updated Guidance: When to Test Symptomatic Pregnant Women




Updated Guidance: Which Tests for Symptomatic Pregnant Women



NAT = nucleic acid testing

Updated Guidance: Test Results for Symptomatic Pregnant Women




Interpretation of Results of Nucleic Acid and Antibody Testing for Suspected Zika Virus Infection

Zika NAT Zika NAT Zika virus and Zika virus PRNT Dengue virus PRNT Interpretation and recommendations (serum) (urine) dengue virus IgM Any result Positive Positive Not indicated Notindicated Acuta Zika virus in faction (either as say Positive Negetive Positive Not indicated Notindicated Acute Zika virus infection (either as say) Suggests acute Zika virus infection Repeat testing on original urine specimen. + If repeat NAT result is positive, interpret as evidence of acute Zira virus intection. Negative on bothesseys Negetive Positive Notindicated Not indicated * If repeat NAT result is negative, repeat Zim wirds (ghi antibody testing on a serum specimen collected b2 weeks after onset or possible exposure or specimen collection date. + If repeat IgM antibody result is positive, interpret as evidence of acute Zila virus intection. + If repeat ight antibody result is not positive, interpret as no evidence of Zira virus intection. Negative or not performed Positive Positive Not indicated Not indicated Acuta Zika Vrus infaction (either assay) Suggests acute Zika virus infliction Repeat testing on original unite specimen. + If repeat NAT result is post in a interpret as evidence of acute Zira virus intection Negative or not performed Negative on both as says Positive Not indicated Not indicated + If repeat NAT result is negative, repeat ZNa wins rgM antibody testing on a serum specimen collected 32 weeks at terionset or possible expositive or specimen collection date. + if repeat ight antibody result is positive, interpret as evidence of acute Zira virus intection. + if repeat ight antibody result is not positive, interpret as no evidence of Zira virus intection. Zika virus infection; timing of infection cannot be determined. Negative or Any non-negative Negative 210 <10 + For patients with no Zila wins exposure prior to the current pregnancy, a positive IgM result not performed result (other assay) represents Zila virus infection during pregnancy. Negative or not performed Any non-negative result (either essay) Negative <10 Any result No evidence of Zika virus infloction Revivirus infection; specific virus cannot be identified; fiming of infection cannot ha datarminad Negative or Any non-negative Negetive 210 210 not performed result (either essey) For patients with no Zha virus exposure prior to the current pregnancy, a positive igid result represents unspectied taxivirus infection during pregnancy. Positive for Zike virus Not performed because PFINT is not recommended Nonetivo or AND negative for dengue virus in certain area of residence (i.e. Puerto Rico) Negetive Presumptive Zika virus infliction; timing of infliction cannot be determined. not performed Positive for Zike virus Not performed because PFINT is not recommended Negetive or Negative AND positive for in certain area of residence Presumptive flavivirus infection; timing of infection cannot be determined. not performed denote vin st 6.e Puerto Rico) Not performed because PENT is not recommended Negetive or Equivocal feither or n certain area of residence Insufficient information for interpretation. Consider repeat testing, Negetive not performed bothesseys) (i.e Puerto Rico) Not performed because PFINT is not recommended Negative or Negative on both No laboratory evidence of Zika virus infection Negetive in cartain area of residence not performed 055045 (i.e Puerto Rico)


TABLE 1. Interpretation of results of nucleic acid and antibody testing for suspected Zika virus infection*, *, *, *, **, **, ** United States, 2017

Oduyebo et al. Update: Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible Zika Virus — United States, July 2017. https://www.cdc.gov/mmwr/volumes/66/wr/mm6629e1.htm?s cid=mm6629e1 w

Updated Guidance: Test Results for Symptomatic Pregnant Women





Updated Guidance: Symptomatic Pregnant Women -- PRNT



*Non-negative terms include positive, equivocal, presumptive positive, or possible. Terms listed here are only examples of assay interpretation terminology because nonnegative serology terminology varies by assay. For explanation of a specific interpretation, refer to the instructions for use for the specific assay performed. <u>https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika</u>


Updated Guidance: Symptomatic Pregnant Women






*For the purposes of this guidance, recent possible Zika virus exposure or Zika virus/flavivirus infection is defined as a possible exposure or infection during the current pregnancy or periconceptional period.


Updated Guidance: Symptomatic Pregnant Women





*For the purposes of this guidance, recent possible Zika virus exposure or Zika virus/flavivirus infection is defined as a possible exposure or infection during the current pregnancy or periconceptional period.


Updated Guidance: Symptomatic Pregnant Women



Asymptomatic Pregnant Women with Possible Zika Virus Exposure

UPDATED INTERIM PREGNANCY GUIDANCE: ASYMPTOMATIC PREGNANT WOMEN WITH POSSIBLE ZIKA VIRUS EXPOSURE

Testing Recommendations and Interpretation of Results for Healthcare Providers



Updated Guidance: Asymptomatic Pregnant Women with Ongoing Possible

ASK PREGNAN

Exposure

ASK PREGNANT WOMEN about

- Possible Zika exposure before and during current pregnancy
- Diagnosis of laboratory-confirmed Zika virus infection before pregnancy
- Presence of symptoms during current pregnancy

Possible sexual exposure before and during the current pregnancy⁶ + Symptoms of laboratory-confirmed Zika virus infection before current pregnancy⁶ + Symptoms of WOMEN ABOUT Zika virus disease during current pregnancy (e.g., fever, rash, conjunctivitis, arthralgia) • If symptoms are reported, refer to symptomatic algorithm Before testing, discuss testing limitations and potential risks of misinterpretations for test results Asymptomatic pregnant women with ongoing possit Zika virus exposure⁴ regnant women with recent possible Zika virus exposure, without or Testing not routinely recommended, but should be considered. WHOM to test? If considering testing, base decisions on patient preferences and values, clinical judgment, a balanced assessment of risks and expected outcomes, and jurisdiction's recommendation If testing is conducted, follow algorithm for symptomatic pregnant women using timeframe from last possible exposure Three times during pregnancy⁶ First test at initiation of prenatal care WHEN to test? WHICH tests? Zika virus NAT (serum and urine) RESULTS Positive Zika virus NAT Negative Zika virus NAT ACUTE ZIKA VIRUS INFECTION NO ZIKA VIRUS RNA DETECTED. ZIKA VIRUS INFECTION INTERPRETATION DURING PREGNANCY CANNOT BE RULED OUT.7

Travel to or residence in any areas with risk for Zika virus transmission before and durino the current pred

COUNSEL PATIENTS on Zika testing

If symptoms are reported, refer to symptomatic algorithm.

Updated Guidance: Asymptomatic Pregnant Women with Ongoing Possible Exposure

WHEN to test? WHICH tests? Test with Zika virus NAT on serum and urine three times during pregnancy

	ASK PREGNANT WOMEN ABOUT	Travel to or residence in <u>any areas with risk for Zika vivus transmission</u> before and during the cournet pregnancy ^{1,2} Possible sexual exposure before and during the cournet pregnancy + A diagnosis of laboratory-confirmed Zika vivus infection before current pregnancy ⁴ + Symptoms of Zika vivus disease during current pregnancy (e.g., fever, rash, conjunctivitis, arthraigia) + If symptoms are reported, refer to symptomatic algorithm.					
7	Before testing, discuss testing limitations and potential risks of misinterpretations for test results.						
	WHOM to test?	Asymptomatic pregnant women with nongoing possible Zika virus exposure'					
	WHEN to test?	Three times during pregnancy ⁶ First test at initiation of prenatal care.					
	WHICH tests?	Zika virus NAT (serum and urine)					
	RESULTS	Positive Zika virus NAT ⁴ Negative Zika virus NAT					
	INTERPRETATION	ACUTE ZIKA VIRUS INFECTION NO ZIKA VIRUS RNA DETECTED. ZIKA VIRUS INFECTION DURING PREGNANCY CANNOT BE RULED OUT?					


Updated Guidance: Asymptomatic Pregnant Women with Ongoing Possible Exposure

REFER TO TABLE 1 FOR INTERPRETATION


(ika NAT (serum)	Zika NAT (urine)	Zika virus and dengue virus IgM	Zika virus PRNT	Dengue virus PRNT	Interpretation and recommendations
Positive	Positive	Any result (either essey)	Not indicated	Notindicated	Acute Zika Vrus infliction
Negstive	Positive	Positive (either as say)	Not indicated	Notindicated	Acute Zika Vrus infection
Negitive	Positive	Negative on bothessays	Notindested	Not indicated	Suggeste sonte Zilla viru infletion Highest factorgio o copialuntes geschen. « If opest (MT neuti in positi en infletport zilla infection e sonte dimensione e sonte geschen in opest (MT neuti in positi en infletport Zilla infectione) infectione e sonte geschen e sonte dimensione e sonte e sonte e sonte e sonte e sonte e sonte dimensione e sonte « If opest (pit infletport e positive), ableport e e anisone of acota Bin neutri inflation « If opest (pit infletport e positive), ableport e e anisone of acota Bin neutri inflation.
Positive	Negative or not performed	Positive (either essay)	Not indicated	Not indicated	Acute Zika Vrus in fection
Positive	Negative or not performed	Negative on bothessays	Notindicated	Not indicated	Suggeste acute Zilla virus infliction Report leading on original inflictions in report IVIT read is provide in relations and acute zilla single inflations in report IVIT read is negative, report Zilla inder gift autibiotyleteting on a secon specialise coludade Zill and read is another operative beginness and acute collection data in report gift actionary executions, relative acute and acute acute the inflictions in relative gift actionary executions beginness and acute acute zilla interviewed in relative gift actionary execution provides acute acute zilla interviewed interviewed in relative gift actionary execution provides acute acute zilla interviewed interviewed in relative gift actionary execution provides acute acute zilla interviewed interviewed interviewed interviewed acute acute acute acute acute a
Nogetivo	Negative or not performed	Any non-negative result (either assay)	210	<10	Zika virusinfectory timing of infection cannot be determined. + For patients with no Ziha vice separate prior for the current pregnancy, a posible (ght result represents Ziha Vice infection obling progenory.
Negativo	Negative or not performed	Any non-negative result (either essay)	< 10	Any result	No evidence of Zika virus infliction
Nogetivo	Negative or not performed	Any non-negative result (either essey)	210	210	Rawkinus infectory specific virus cannot be identified; timing of infection cannot be determined + For palents with no 2he wirus expresse prior to the current preparery, a positive igit result represents corporated themistre interaction during preparery.
Nogetivo	Negative or not performed	Positive for Zike virus AND negative for dengue virus	Not performed because PENT is not recommended in cartain area of residence (Le Puerto Rico)		Presumptive Zika virus inflaction; fining of inflaction cannot be determined.
Negative	Negative or not performed	Positive for Zike virus AND positive for dengue virus	Not performed because P in cartain area of residence (i.e. Pluerto Rico)	PhT is not recommended 19	Presumptive flavivirus infector; timing of infection cannot be determined.
Negstive	Negative or not performed	Equivocal (sither or bothesseys)	Not performed because P in cartain area of residence (i.e. Pluerto Rico)	FINITis not recommended e	Insufficient information for interpretation. Consider repeat testing.
Negstive	Negative or not performed	Negative on both essays	Not performed because P in cartain area of residenc (i.e. Pluerto Rico)	Ph/Tis not recommended	No laboratory evidence of Zika virus infection

- 1						
	ASK PREGNANT WOMEN ABOUT	Travel to or residence in any areas with risk for Zika virus transmission before and during the normet pregnancy ¹² Possible sexual exposure before and during the normet neurant pregnancy. A diagnosis of televitory-confirmed full karvius infection before current pregnancy ¹ • Symptoms of Zika virus disease during current pregnancy (e.g., fever, rash, conjunctivitis, arthralgia) • If symptoms are reported, refer to symptomatic algorithm.				
		Before testing, discuss testing limitations and potential risks of misinterpretations for test results.				
	WHOM to test?	Asymptomatic pregnant women with ongoing possible Zika virus exposure ⁴ If considering testing, base detailors on patient preferences and values, clinical judgment, a balanced assessment of risks and expected outcomes, and jurisdiction's recommendations If testing is conducted, follow algorithm for symptomatic pregnant women using timeframe from last possible exposure.				
	WHEN to test?	Three times during pregrancy ⁴ First test at initiation of prenatal care.				
	WHICH tests?	Zika virus NAT (serum and urine)				
	RESULTS	Positive Zika virus NAT ⁴ Negative Zika virus NAT				
	INTERPRETATION	ACUTE ZIKA VIRUS INFECTION NO ZIKA VIRUS RNA DETECTED. ZIKA VIRUS INFECTION DURING PREGNANCY CANNOT BE RULED OUT.				

Updated Guidance: Asymptomatic Pregnant Women with Recent Possible Exposure, but without Ongoing Possible Exposure



Updated Guidance: Asymptomatic Pregnant Women with Recent Possible Exposure, but without Ongoing Possible Exposure



If testing is conducted, follow algorithm for symptomatic pregnant women using timeframe from last possible exposure.

Initial Evaluation Of Infants Whose Mothers Had Possible Zika Virus Exposure During Pregnancy But Were Not Tested

- Comprehensive physical exam
 - » Head circumference, weight, height measurements
 - » Neurologic assessment
- Standard newborn hearing assessment
- Based on level of possible exposure, consider
 - » Head ultrasound
 - » Ophthalmologic exam



• Based on evaluation, consider Zika virus laboratory testing of infant

https://www.cdc.gov/zika/hc-providers/infants-children/evaluation-testing.html

Updated Guidance: Asymptomatic Pregnant Women with Possible Zika Virus Exposure

Jurisdictions may recommend testing of asymptomatic pregnant women for clinical decision-making or as part of Zika virus infection surveillance.

Updated Guidance: Testing of Placental and Fetal Tissues

Morbidity and Mortality Weekly Report

Evaluation of Placental and Fetal Tissue Specimens for Zika Virus Infection — 50 States and District of Columbia, January–December, 2016

Sarah Reagan-Steiner, MD¹; Regina Simeone, MPH²; Elizabeth Simon, MPH²; Julu Bhatnagar, PhD¹; Titilope Oduyebo, MD³; Rebecca Free, MD⁴; Amy M. Denison, PhD¹; Demi B. Rabeneck, MS¹; Sascha Ellington, MSPH²; Emily Petersen, MD²; Joy Gary, DVM¹; Gillian Hale, MD¹; M. Kelly Keating, DVM¹; Roosecelis B. Martines, MD¹; Atis Muehlenbachs, MD¹; Jana Ritter, DVM¹; Ellen Lee, MD⁵; Alexander Davidson, MPH⁵; Erin Conners, PhD⁵; Sarah Scotland, MPH⁶; Kayleigh Sandhu, MPH⁶; Andrea Bingham, PhD⁷; Elizabeth Kassens⁷; Lou Smith, MD⁸; Kirsten St. George, MD⁸; Nina Ahmad, MD⁸; Mary Tanner, MD^{9,10}; Suzanne Beavers, MD¹¹; Brooke Miers, MS^{1,12}; Kelley VanMaldeghem, MPH²; Sumaiya Khan, MPH²; Ingrid Rabe, MBChB¹³; Carolyn Gould, MD¹³; Dana Meaney-Delman, MD¹⁴; Margaret A. Honein, PhD²; Wun-Ju Shieh, MD¹; Denise J. Jamieson, MD³; Marc Fischer, MD¹³; Sherif R. Zaki, MD¹; U.S. Zika Pregnancy Registry Collaboration; Zika Virus Response Epidemiology and Surveillance Task Force Pathology Team

Updated Guidance

Testing of placental tissues not routinely recommended for asymptomatic women without ongoing possible exposure when infant or fetus does not have Zikaassociated birth defects

Recommendations to Prevent Zika Virus Infection Have not Changed

Do Not Travel	 Pregnant women should not travel to areas with risk for Zika virus transmission 		
Prevent Mosquito Bites	 If a pregnant woman lives in or travels to an area with risk for Zika virus transmission, she should take steps to prevent mosquito bites 		
Prevent Sexual Transmission	 Take steps to prevent sexual transmission of Zika from a partner who lives in or traveled to an area with risk for Zika virus transmission 		

Clinical Tools for Implementing Guidance

PRETEST COUNSELING CONVERSATION GUIDE FOR HEALTHCARE PROVIDERS FOR ASYMPTOMATIC PREGNANT WOMEN WITH ONGOING EXPOSURE TO ZIKA COUNSELING CONVERSATION GUIDE FOR HEALTHCARE PROVIDERS This quide describes recomm women with ongoing expo FOR ASYMPTOMATIC PREGNANT WOMEN WHO WERE RECENTLY EXPOSED TO ZIKA complexity of Zika testing and understand what they are beir BUT DO NOT HAVE OF PRETEST COUNSELING CONVERSATION GUIDE FOR HEALTHCARE PROVIDERS Pregnant women comin FOR PREGNANT WOMEN WITH SYMPTOMS OF ZIKA avoiding technical terms a This guide provides talking points for ently traveled to an area with risk of or if your state or local jurisdiction reco Recommendation The guide describes economendations for conducting predenting counseling for apmentantic pregnant vanues with possible score spopulate (they or the score between the score be women who do not have ongoing exposu Provide the patient with informa Pregnant women who may have on the complexity of Zika testing information and expressing emp Pregnant women coming in for Zika testing may feel worried or anxious. Support them by providing them with clear and easy-to-understand information and expressing empathy by acknowledging their concerns and feelings during pretesting counseling. Recommendation Recommendation Sample Script Inform the patient that it can be challenging to understand test rest, and provide them with information the type of test you will be conducted for asymptomatic pregnant women without ongoing Provide the patient with information Use one of the two following sentences to begin the discussion on why you will be testing them for Zika and a brief overview of what You may be at risk for having Zika since you or your sex partner recently traveled to (replace "recently traveled to" with "the in" as appropriate) an area with risk of Zika within the past 12 weeks and you have had (replace "have had" with "during your pregnancy your previously had" as appropriate) symptoms of to expect Inform patients of what each OR/AND possible test result could mean t their pregancy 2. You may be at risk of having 7/ka because you recently had sex without a condom with a person who traveled to 'mplace "traveled to" with "lives in" as nou may be a rack on many a native because you recently need as within a control in with a period within develoa to be appropriate a race with risk of Zika within the pest 12 weeks and you have had (replace 'have had' with 'during your pregre as appropriate) symptoms of Zika. ously dev oped If Zika test results are positive. Since you were exposed to Zika and are experiencing symptoms (replace "are experiencing" with 'during your pregnancy you previously ex erienced" as appropriate). I think it is best to move forward with testing you for Zika. Before we begin, I would like to tell you what to expect throughout this process. If Zika test results are not clearly positive or negative. You will need a combination of tests to determine whether or not you have Zika. Finding out if you have Zika can require up to three different kinds of tests because the result of one test may require more testings for find out if you recently had a Zika inflection. The tests we use to detect Zika can detect other similar visces often found in tests maraneses with the Zika. Sometimes were affects, and may not know which type of virus you were inflected with. Each test result is important, because it may help me decide how best to care for you during prepanary. Patients should be informed that a combination of Zika tests will be required before a final result is determined If Zika test results are negative I want to be sure we take all of the necessary steps to make sure your results are accurate. Each test can take different amounts of time to receive results, which I know can be frustrating. As your healthcare provider I am here to answer any questions you may have. · Reassure the patient that this method of testing is normal Consider providing the fact sheet What You Should Know About Zika Wrus Testing for Pregnant Women with Symptoms of Zika. CS273696A July 21, 2017 Let the patient know that you will be ordering two tests; one to look for Zika RNA and one to look for Zika I am going to start the testing process by ordering two tests: The first test looks for pieces of Zika virus, known as RNA. RNA can be found in blood and urine. The second test looks for Zika antibodies, which are proteins that your body makes to fight off a Zika infection. antibodies. Define these terms as they may be unfamiliar Zika test results can be difficult to interpret. If you've had exposure to Zika virus or another similar virus before this pregnancy, it's possible that you've been ected before, and this could affect today's test results

CDC's Response to **Zika WHAT YOU SHOULD KNOW** ABOUT ZIKA VIRUS TESTING

For Pregnant Women Who Have Ongoing Exposure to Zika but No Symptoms

If you or your sex partner live in an area with risk of Zika or frequently travel to such an area, you may have been exposed to Zika diving pregnancy or before you became pregnant. You may have questions about Zika and you may want to know how to find out if you've been infected. Keep reading to learm nore.

Zika testing is complex

In general, testing for Zika can include looking for Zika genetic material (pieces of the virus called RNA) and antibodies that the body would make to fight a Zika infection.

- Testing for Zika genetic material is recommended for you because it can tell your doctor if you were recently infected with Zika.
- Testing for Zika antibodies is not routinely recommended for pregnant women who have ongoing exposure to Zika but no symptoms because the results cannot be interpreted. We know that Zika antibodies can stay in the body for several months. If you lived in or frequently traveled to an area where local mosquitoes spread Zika, you may have been infected before pregnancy. This means you may have already developed antibodies against Zika before you became pregnant. Because of this, Zika antibody test results may not tell your doctor if you were infected in the past or if you were infected more recertly during your current pregnancy. This means that these results would not tell us if your pregnancy is at risk from Zika infection.





Sharing Up-to-Date Information

- Providing updated clinical guidance
- Responding to your inquiries:
 - » Email: <u>ZikaMCH@cdc.gov</u>
 - » Zika Pregnancy Hotline: 770-488-7100
 - » <u>CDC-INFO</u>: (800-232-4636)



http://www.cdc.gov/zika

CDC'S Response to Zika

Pregnancy Outcomes After Maternal Zika Virus Infection During Pregnancy — US Territories, January 1, 2016–April 25, 2017

US Zika Pregnancy Registry and Puerto Rico Zika Active Pregnancy Surveillance System

Dana Meaney-Delman, MD, MPH Co-Lead, Pregnancy and Birth Defects Task Force Centers for Disease Control and Prevention





U.S. Department of Health and Human Services Centers for Disease Control and Prevention

Zika Pregnancy and Infant Registries: US Zika Pregnancy Registry and Zika Active Pregnancy Surveillance System (ZAPSS)

Purpose of registries

- To monitor pregnancy and infant outcomes in pregnancies with laboratory evidence of possible Zika virus infection
 - Estimate number of infants with birth defects
 - Provide data to inform phenotype of congenital Zika syndrome
 - Help ensure infants are linked to care



Zika Pregnancy and Infant Registries: Who is Included

Pregnant women in the 50 US states and US territories.

Pregnant women with laboratory evidence of possible Zika virus infection (regardless of whether they have symptoms) and their exposed infants.

Infants with laboratory evidence of congenital Zika virus infection (regardless of whether they have symptoms) and their mothers.

Zika Pregnancy and Infant Registries: A Comparison

Registry Feature	US Zika Pregnancy Registry	Zika Active Pregnancy Surveillance System
Location	50 States and District of Columbia, US territories and Freely Associated States <u>excluding</u> Puerto Rico	Puerto Rico
Maternal Eligibility	Pregnant women with laboratory evidence of Zika	Pregnant women with laboratory evidence of Zika
Infant Follow-Up	Through 1 st year of life	Through 3 rd year of life




Pregnancy Outcomes Following Zika Virus Infection during Pregnancy in US Territories



- Provides data from women and infants living in American Samoa, the Commonwealth of Puerto Rico, the Federated States of Micronesia, the Republic of the Marshall Islands, and the US Virgin Islands
- Data reported to the US Zika Pregnancy Registry and the Puerto Rico Zika Active Pregnancy Surveillance System from January 1, 2016- April 25, 2017

Zika-Related Pregnancy Outcomes in US Territories



Results from Zika Pregnancy and Infant Registries

Findings	US States and DC USZPR ¹ % (95% CI)	US Territories USZPR/ZAPPS ² % (95% CI)
Symptomatic vs. Asymptomatic		
% Symptomatic with birth defects	8 (4-13)	5 (4-6)
% Asymptomatic with birth defects	12 (7-19)	7 (4-11)
Birth Defects by Trimester of Infection at DX		
First trimester	15 (8-26)	8 (5-12)
Second trimester		5 (4-7)
Third trimester		4 (3-6)

 Reynolds MR, Jones AM, Petersen EE, et al. Vital Signs: Update on Zika Virus–Associated Birth Defects and Evaluation of All U.S. Infants with Congenital Zika Virus Exposure — U.S. Zika Pregnancy Registry, 2016. MMWR Morb Mortal Wkly Rep 2017;66:366-373. DOI: <u>http://dx.doi.org/10.15585/mmwr.mm6613e1</u>.

Shapiro-Mendoza CK, Rice ME, Galang RR, et al. Pregnancy Outcomes After Maternal Zika Virus Infection During Pregnancy — U.S. Territories, January 1, 2016–April 25, 2017. MMWR Morb Mortal Wkly Rep 2017;66:615-621. DOI: http://dx.doi.org/10.15585/mmwr.mm6623e1

Impact of Third Trimester Infections

- 34% of 3rd trimester infections were symptomatic
- Among mothers diagnosed with infection in the 3rd trimester, 4% had an infant or fetus with Zika virus-associated birth defects

Birth defects observed among pregnancies with symptom onset or positive laboratory testing during any trimester

Infant Follow-up in US Territories

Recommended infant screening and testing reported to Zika pregnancy and infant registries	Live-born infants <u>with</u> birth defects %	Live-born infants <u>without</u> birth defects %	Total %
Infant Zika virus testing	55%	59%	59%
Postnatal neuroimaging	59%	52%	52%
Hearing screening	91%	78%	79%

Public Health Implications

- Highest proportion of Zika-associated birth defects among those with Zika virus infection during first and early second trimester of pregnancy
 - » More data are needed to explore whether women infected in the third trimester are at risk for:
 - having a baby with birth defects
 - other adverse pregnancy outcomes
- Identification and follow-up care of infants can facilitate timely and appropriate clinical intervention services and assessment of future needs
- Monitoring of affected pregnancies and continued follow-up care for infant is critical to elucidating the impact of congenital Zika virus infection



What You Can Do to Help

Educate families on Zika virus prevention

Ask about possible Zika virus exposure

Provide all needed tests and follow-up care


Support infants and families

Report to the Zika virus pregnancy and infant registries

Summary

- Zika virus infection diagnosed during any trimester of pregnancy poses a risk to the fetus
- The absence or presence of symptoms in patients with confirmed Zika virus infection does not appear to affect the risk of birth defects
- Healthcare providers can educate patients, follow CDC recommendations for screening and testing, support infants and families, and report to the Zika pregnancy and infant registries

Congenital Zika syndrome is a pattern of birth defects in babies infected with Zika during pregnancy



CDC'S Response to Zika

Zika Virus Infection: Pediatric Ophthalmologic Findings

S. Grace Prakalapakorn, MD, MPH Assistant Professor of Ophthalmology and Pediatrics Duke University




U.S. Department of Health and Human Services Centers for Disease Control and Prevention






Ophthalmology 101



Normal Retina




Wikimedia Commons

Arizona Eye Institute

Ocular Findings in Congenital Zika Infection

Ocular Findings Associated with Congenital Zika Virus Infection

- Ocular abnormalities have been identified in infants with and without microcephaly
- Abnormalities have been found in the anterior and posterior ocular structures
- Cortical visual impairment might be the most common cause of blindness among children with congenital Zika syndrome




Macular and Optic Nerve Findings

Commonly reported macular findings

- Macular mottling
- Chorioretinal atrophy

Commonly reported optic nerve findings

- Hypoplasia
- Increased cup to disk ratio
- Pallor



Macular mottling, chorioretinal atrophy, and optic nerve hypoplasia

Subretinal hemorrhages, vascular tortuosity, abnormal vessel termination, and focal area of dilation


Ventura CV, et al. Ophthalmological findings in infants with microcephaly and presumable intra-uterus Zika virus infection. Arq Bras Oftalmol. 2016 Feb;79(1):1-3. Miranda HA, et al. Expanded Spectrum of Congenital Ocular Findings in Microcephaly with Presumed Zika Infection. Ophthalmology. 2016 Aug;123(8):1788-94..

Other Ocular Findings

- Congenital glaucoma
- Iris colobomas
- Microphthalmia
- Subluxation of the lens
- Cataract
- Intraocular calcification



Congenital Glaucoma



Iris colobomas



Microphthalmia

de Paula Freitas, et al. Anterior-Segment Ocular Findings and Microphthalmia in Congenital Zika Syndrome. Ophthalmology. 2017 Jul. [Epub ahead of print] Yepez JB, et al. Ophthalmic Manifestations of Congenital Zika Syndrome in Colombia and Venezuela. JAMA Ophthalmol. 2017 May 1;135(5):440-445

Risk Factors for Ocular Findings

- Smaller head circumference
- Microcephaly
- Other CNS abnormalities
- Earlier trimester infection in pregnancy
- Arthrogryposis



Ventura CV, et al. Risk Factors Associated With the Ophthalmoscopic Findings Identified in Infants With Presumed Zika Virus Congenital Infection. JAMA Ophthalmol. 2016 Aug 1;134(8):912-8. Zin AA, et al. Screening Criteria for Ophthalmic Manifestations of Congenital Zika Virus Infection. JAMA Pediatr. 2017 Jul 17. [Epub ahead of print] Moore CA, Staples JE, Dobyns WB, et al. Characterizing the Pattern of Anomalies in Congenital Zika Syndrome for Pediatric Clinicians. JAMA Pediatr 2017;171:288-95.

Infants with Possible Zika Virus Infection WITHOUT Microcephaly



Hypopigmented retinal lesion


Chorioretinal atrophy

-Ventura CV, et al. Zika: neurological and ocular findings in infant without microcephaly. Lancet. 2016 Jun 18;387(10037):2502.

-Honein MA, Dawson AL, Petersen EE, et al. Birth Defects Among Fetuses and Infants of US Women With Evidence of Possible Zika Virus Infection During Pregnancy. JAMA. 2017;317(1):59-68. -Ventura CV, et al. First Travel-Associated Congenital Zika Syndrome in the US: Ocular and Neurological Findings in the Absence of Microcephaly. Ophthalmic Surg Lasers Imaging Retina. 2016 Oct 1;47(10):952-955.

-de Paula Freitas, et al. Anterior-Segment Ocular Findings and Microphthalmia in Congenital Zika Syndrome. Ophthalmology. 2017 Jul. [Epub ahead of print

Eye findings in Infants Without CNS Abnormalities



Optic nerve hypoplasia, chorioretinal atrophy, and macular mottling

Optic nerve hypoplasia and chorioretinal atrophy

Zin AA, et al. Screening Criteria for Ophthalmic Manifestations of Congenital Zika Virus Infection. JAMA Pediatr. 2017 Jul 17. [Epub ahead of print]

Eye Findings in Congenital Infections

	Zika	Toxoplasmosis	Rubella	CMV	Herpes Simplex	Syphilis
Conjunctivitis					+	
Keratitis					+	+
Macular Mottling	+ focal pigmentary clumping		+ granular (Salt-and-pepper retinopathy)			+ granular (Salt-and- pepper retinopathy)
Chorioretinal Atrophy	+	+				
Optic Nerve abnormalities	Hypoplasia, cupping, pallor		pallor	pallor		
Cataract	÷		+	÷	+	
Microphthalmia	÷		+	÷		
Iris Coloboma	+					
Active inflammation:		+	+		4	-

CDC Recommendations: Ophthalmic screening

Who should be referred for screening and when?

- Before hospital discharge:
 - » Infant whose mother has risk factors for maternal Zika virus infection (travel to or residence in an area with risk of Zika or sex with a partner who traveled to or resided in such an area)

AND

» Maternal test results are not available

AND

- » There is a concern about infant follow-up care
- Before 1 month of age:
 - » All infants with laboratory evidence of congenital Zika virus infection


OR

- » Abnormal findings consistent with CZS
- Follow up should occur
 - » If the ophthalmologic examination within the first month of age is normal
 - » Another complete examination at 3 months of age

Russell K, Oliver SE, Lewis L, et al. Update: Interim Guidance for the Evaluation and Management of Infants with Possible Congenital Zika Virus Infection — United States, August 2016. MMWR Morb Mortal Wkly Rep 2016;65:870–878.

Screening should include

- Ophthalmologic assessment:
 - » Visual acuity assessment
 - » Intraocular pressure measurements
 - » Slit lamp examination
 - » Dilated fundus examination
- Resources for children with vision impairment or loss
 - » Low vision specialist
 - » Early intervention



National Eye Institute

How can primary care providers help?

- For infants without laboratory evidence of Zika virus infection but for whom suspicion for congenital Zika virus infection remains
 - » Consider referral to an ophthalmologist before hospital discharge or within 1 month of birth
- Outpatient management of infants with possible congenital Zika exposure but without abnormalities consistent with CZS
 - » During routine infant follow-up with primary care providers, at each well child visit
 - Vision screening, including assessment of visual regard
 - Referral to an ophthalmologist for any caregiver or provider concern
- Tips for screening vision in young infants
 - » For very young infants (1-2 months of age): test wince to light
 - » At about 3 months of age: fix and follow
 - » Test vision with both eyes open first, then try one eye at a time

Russell K, Oliver SE, Lewis L, et al. Update: Interim Guidance for the Evaluation and Management of Infants with Possible Congenital Zika Virus Infection — United States, August 2016. MMWR Morb Mortal Wkly Rep 2016;65:870–878.

Summary

- Declining transmission and new data on Zika virus persistence increase complexity of testing
- Updated guidance places emphasis on shared decision-making based on patient preferences, clinical judgment, and in line with jurisdictional recommendations
- Zika virus infection poses a risk to all pregnancies, regardless of timing of possible exposure and symptoms
- Congenital Zika virus infection can lead to poor ophthalmologic outcomes in the presence and absence of other birth defects

Thank you!

More information on Zika: www.cdc.gov/zika

For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.



Today's webinar will be archived

When: A few days after the live call

What: All call recordings (audio, webinar, and transcript)

Where: On the COCA Call webpage https://emergency.cdc.gov/coca/calls/2017/callinfo_072717.asp

74

Continuing Education for COCA Calls

All continuing education (CME, CNE, CEU, CECH, ACPE, CPH, and AAVSB/RACE) for COCA Calls are issued online through the <u>CDC Training</u> & <u>Continuing Education Online system (http://www.cdc.gov/TCEOnline/)</u>.

Those who participated in today's COCA Call and who wish to receive continuing education should complete the online evaluation by June 3, 2017 with the course code WC2286. Those who will participate in the on demand activity and wish to receive continuing education should complete the online evaluation between June 3, 2017 and May 4, 2019 will use course code WD2286.

Continuing education certificates can be printed immediately upon completion of your online evaluation. A cumulative transcript of all CDC/ATSDR CE's obtained through the CDC Training & Continuing Education Online System will be maintained for each user.

Thank you for joining!



Centers for Disease Control and Prevention Atlanta, Georgia http://emergency.cdc.gov/coca

Join the COCA Mailing List

Receive information about:

- Upcoming COCA Calls
- Health Alert Network notices
- CDC public health activations
- Emerging health threats
- Emergency preparedness and response conferences and training opportunities



COCA MAILING LIST

Get emails about upcoming COCA Calls, training resources, and other public health updates.

http://emergency.cdc.gov/coca